6533b827fe1ef96bd1285aeb
RESEARCH PRODUCT
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Luigi BagellaLuigi BagellaMario Federicosubject
Health Toxicology and Mutagenesislcsh:Biotechnologylcsh:MedicineReview ArticleNeoplasmslcsh:TP248.13-248.65GeneticsAnimalsHumansCancer epigeneticsMolecular BiologyHistone deacetylase 5biologyHDAC11Histone deacetylase 2HDAC10lcsh:RGeneral MedicineHistone Deacetylase InhibitorsHistoneBiochemistryAcetylationHematologic Neoplasmsbiology.proteinCancer researchMolecular MedicineHistone deacetylaseBiotechnologydescription
The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors bothin vitroandin vivo. Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-12-01 | Journal of Biomedicine and Biotechnology |